Strange Bedfellows: Generics Firms Join Big Pharma In Opposing US Price Negotiation Legislation
Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the US generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.
You may also be interested in...
Joe Manchin’s refusal to vote in favor of the Biden administration’s Build Back Better legislation could prove to be a boon for the US biosimilars industry, following weeks of condemnation from the Association for Accessible Medicines.
Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.
The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.